US2019290755A1PendingUtilityA1

B-cell reduction using cd37-specific and cd20-specific binding molecules

59
Assignee: APTEVO RES & DEVELOPMENT LLCPriority: Jul 25, 2005Filed: Oct 26, 2018Published: Sep 26, 2019
Est. expiryJul 25, 2025(expired)· nominal 20-yr term from priority
Inventors:Laura Sue GrosmaireMartha Hayden-LedbetterJeffrey A. LedbetterPeter Armstrong ThompsonSandy Alexander SimonWilliam Brady
A61P 3/10A61P 37/06A61P 35/02A61P 35/00A61P 37/02A61P 43/00A61P 37/00A61P 27/02A61P 29/00A61P 25/00A61P 21/00A61P 17/00A61P 21/04A61P 17/06A61P 1/04A61P 19/02C07K 2317/56C07K 2317/75C07K 16/2896A61K 2039/545A61K 2039/507C07K 2317/76C07K 2317/567C07K 2317/734C07K 2317/622A61K 39/3955C07K 16/3061C07K 2317/72A61K 2039/505C07K 2317/52C07K 2317/565C07K 16/30C07K 2317/53A61K 39/39558C07K 2317/73C07K 2317/24C07K 16/2887A61K 45/06C07K 2317/732A61K 39/395
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition; the invention provides humanized CD37-specific binding molecules.

Claims

exact text as granted — not AI-modified
1 .- 117 . (canceled) 
     
     
         118 . A humanized or chimeric CD37-specific binding molecule comprising a binding domain and immunoglobulin CH2 and CH3 domains, wherein the binding domain comprises:
 a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 61;   a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 64;   a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 66;   a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 63;   a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 65; and   a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 67 or 68.   
     
     
         119 . A pharmaceutical composition comprising a humanized or chimeric CD37-specific binding molecule and one or more pharmaceutically acceptable carriers or additives, wherein the CD37-specific binding molecule comprises a binding domain and immunoglobulin CH2 and CH3 domains, wherein the binding domain comprises:
 a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 61;   a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 64;   a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 66;   a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 63;   a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 65; and   a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 67 or 68.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.